Comment on Komé et al. One Size Does Not Fit All: Understanding Microdosing Semaglutide for Diabetes in Multidose Pens.
作者信息
Tejera-Pérez Cristina
机构信息
Department of Endocrinology and Nutrition, University Hospital Complex of Ferrol (CHUF/SERGAS), A Coruña, Spain.
Epigenomics in Endocrinology and Nutrition Group, Epigenomics Unit, Health Research Institute of Santiago de Compostela (IDIS), University Hospital Complex of Santiago de Compostela (CHUS/SERGAS), Santiago de Compostela, Spain.
出版信息
Diabetes Care. 2025 Jul 1;48(7):e93. doi: 10.2337/dc25-0566.
Abstract
摘要
相似文献
1
Comment on Komé et al. One Size Does Not Fit All: Understanding Microdosing Semaglutide for Diabetes in Multidose Pens.对科梅等人的评论。“一刀切”并不适用：理解多剂量笔中用于糖尿病治疗的司美格鲁肽微剂量给药
Diabetes Care. 2025 Jul 1;48(7):e93. doi: 10.2337/dc25-0566.
2
One Size Does Not Fit All: Understanding Microdosing Semaglutide for Diabetes in Multidose Pens.一刀切并不适用于所有情况：了解多剂量笔式司美格鲁肽用于糖尿病的微剂量给药
Diabetes Care. 2025 Mar 1;48(3):e25-e27. doi: 10.2337/dc24-2575.
3
Indirect comparative efficacy and safety of tirzepatide 10 and 15 mg versus semaglutide 2.4 mg for the management of obesity and overweight in patients with type 2 diabetes.替尔泊肽10毫克和15毫克与司美格鲁肽2.4毫克治疗2型糖尿病患者肥胖和超重的间接比较疗效与安全性
Diabetes Obes Metab. 2025 Jun 19. doi: 10.1111/dom.16508.
4
Comparative efficacy of 5 sodium glucose cotransporter 2 inhibitor and 7 glucagon-like peptide 1 receptor agonists interventions on cardiorenal outcomes in type 2 diabetes patients: A network meta-analysis based on cardiovascular or renal outcome trials.基于心血管或肾脏结局试验的 2 型糖尿病患者中 5 种钠-葡萄糖共转运蛋白 2 抑制剂和 7 种胰高血糖素样肽 1 受体激动剂干预措施对心肾结局的比较疗效：网络荟萃分析。
Medicine (Baltimore). 2021 Jul 30;100(30):e26431. doi: 10.1097/MD.0000000000026431.
5
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.司美格鲁肽对 2 型糖尿病患者慢性肾脏病的影响。
N Engl J Med. 2024 Jul 11;391(2):109-121. doi: 10.1056/NEJMoa2403347. Epub 2024 May 24.
6
Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis.在非糖尿病肥胖患者中，司美格鲁肽用于减肥的疗效和安全性：系统评价和荟萃分析。
J ASEAN Fed Endocr Soc. 2022;37(2):65-72. doi: 10.15605/jafes.037.02.14. Epub 2022 Aug 23.
7
Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials.皮下注射替西帕肽与司美格鲁肽治疗 2 型糖尿病成人患者的疗效比较：一项随机对照试验的系统评价和网络荟萃分析。
Diabetologia. 2024 Jul;67(7):1206-1222. doi: 10.1007/s00125-024-06144-1. Epub 2024 Apr 13.
8
Exercise interventions for cerebral palsy.脑瘫的运动干预
Cochrane Database Syst Rev. 2017 Jun 11;6(6):CD011660. doi: 10.1002/14651858.CD011660.pub2.
9
Glucagon-Like Peptide-1 Receptor Agonists Use Does Not Increase the Risk for Acute Pancreatitis and Is Associated With Lower Complications in Patients With Type 2 Diabetes Who Develop Acute Pancreatitis: A Multicenter Analysis.胰高血糖素样肽-1受体激动剂的使用不会增加急性胰腺炎的风险，且与2型糖尿病并发急性胰腺炎患者较低的并发症发生率相关：一项多中心分析。
Am J Gastroenterol. 2025 May 13. doi: 10.14309/ajg.0000000000003525.
10
Obesity and Schizophrenia: Results of a Feasibility Study with Semaglutide to Assist Weight Loss.肥胖与精神分裂症：司美格鲁肽辅助减肥的可行性研究结果
Adv Ther. 2025 Jun 19. doi: 10.1007/s12325-025-03261-0.
本文引用的文献
1
Alternative dosing regimens of GLP-1 receptor agonists may reduce costs and maintain weight loss efficacy.胰高血糖素样肽-1受体激动剂的替代给药方案可能会降低成本并维持减肥效果。
Diabetes Obes Metab. 2025 Apr;27(4):2251-2258. doi: 10.1111/dom.16229. Epub 2025 Feb 14.
2
One Size Does Not Fit All: Understanding Microdosing Semaglutide for Diabetes in Multidose Pens.一刀切并不适用于所有情况：了解多剂量笔式司美格鲁肽用于糖尿病的微剂量给药
Diabetes Care. 2025 Mar 1;48(3):e25-e27. doi: 10.2337/dc24-2575.
3
Compounded GLP-1 and Dual GIP/GLP-1 Receptor Agonists: A Statement from the American Diabetes Association.复合胰高血糖素样肽-1及双重葡萄糖依赖性促胰岛素多肽/胰高血糖素样肽-1受体激动剂：美国糖尿病协会声明
Diabetes Care. 2025 Feb 1;48(2):177-181. doi: 10.2337/dci24-0091.
Zotero 插件